Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.55 |
| ▸ | POLB | P06746 | 2/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.55 |
| ▸ | PDE4B | Q07343 | 12/20 | 0.53 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.46 |
| ▸ | WNT3A | P56704 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5564330 | 0.74 | PDE4B (0.55) | ALDH1A1POLBCYP2C19PDE4BALOX15 | |
| SCHEMBL6158071 | 0.71 | PDE4B (0.50) | ALDH1A1POLBCYP2C19PDE4BMAPT | |
| SCHEMBL31314527 | 0.70 | MEN1 (0.70) | ALDH1A1POLBCYP2C19PDE4BMAPT | |
| SCHEMBL2848397 | 0.70 | MEN1 (0.70) | ALDH1A1POLBCYP2C19PDE4BMAPT | |
| SCHEMBL22713955 | 0.70 | PDE4B (1.00) | PDE4B | |
| SCHEMBL30506315 | 0.69 | HSD17B2 (0.76) | ALDH1A1POLBCYP2C19MAPTCYP1A2 | |
| SCHEMBL1660365 | 0.69 | HSD17B2 (0.76) | ALDH1A1POLBCYP2C19MAPTCYP1A2 | |
| SCHEMBL11705162 | 0.69 | CTNNB1 (0.70) | ALDH1A1POLBCYP2C19PDE4BMAPT | |
| SCHEMBL29578705 | 0.69 | MEN1 (0.73) | ALDH1A1POLBCYP2C19PDE4BMAPT | |
| SCHEMBL515746 | 0.69 | MEN1 (0.73) | ALDH1A1POLBCYP2C19PDE4BMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0819123-B1 | 1,3-DIHYDRO-1-(PHENYLALKENYL)-2H-IMIDAZOL-2-ONE DERIVATIVES HAVING PDE IV AND CYTOKINE INHIBITING ACTIVITY | JANSSEN PHARMACEUTICA NV (BE) | 2007-12-12 | — | — | EP | disclosed |
| EP-0832071-B1 | 1,3-DIHYDRO-2H-IMIDAZOL-2-ONE DERIVATIVES HAVING PDE IV AND CYTOKININ INHIBITING ACTIVITY | JANSSEN PHARMACEUTICA NV (BE) | 2005-09-28 | — | — | EP | disclosed |
| US-6403805-B1 | SUCH AS 1-((1-(3-(CYCLOPENTYLOXY)-4-METHOXYPHENYL) CYCLOPROPYL)METHYL)-1,3-DIHYDRO-2H-IMIDAZOL-2-ONE FOR ALLERGIES, ATOPIC AND INFLAMMATORY DISEASES WHEREIN ACTIVITY OF PHOSPHODIESTERASE IS ALTERED | JANSSEN PHARMACEUTICA N.V. (BE) | 2002-06-11 | — | — | US | disclosed |
| US-20020068830-A1 | 1,3-DIHYDRO-1-(PHENYLALKYL)-2H-IMIDAZOL-2-ONE DERIVATIVES | FREYNE EDDY JEAN EDGARD (BE) | 2002-06-06 | — | — | US | disclosed |
| EP-0819122-B1 | 1,3-DIHYDRO-1-(PHENYLALKYL)-2H-IMIDAZOL-2-ONE DERIVATIVES HAVING PDEIV AND CYTOKINE ACTIVITY | JANSSEN PHARMACEUTICA NV (BE) | 2002-03-06 | — | — | EP | disclosed |
| US-5994376-A | PHOSPHODIESTERASE INHIBITOR | JANSSEN PHARMACEUTICA, N.V. (BE) | 1999-11-30 | — | — | US | disclosed |
| EP-0832071-A1 | 1,3-DIHYDRO-2H-IMIDAZOL-2-ONE DERIVATIVES HAVING PDE IV AND CYTOKININ INHIBITING ACTIVITY | JANSSEN PHARMACEUTICA N.V. (BE) | 1998-04-01 | — | — | EP | disclosed |
| EP-0819122-A1 | 1,3-DIHYDRO-1-(PHENYLALKYL)-2H-IMIDAZOL-2-ONE DERIVATIVES HAVING PDEIV AND CYTOKINE ACTIVITY | JANSSEN PHARMACEUTICA N.V. (BE) | 1998-01-21 | — | — | EP | disclosed |
| EP-0819123-A1 | 1,3-DIHYDRO-1-(PHENYLALKENYL)-2H-IMIDAZOL-2-ONE DERIVATIVES HAVING PDE IV AND CYTOKINE INHIBITING ACTIVITY | JANSSEN PHARMACEUTICA N.V. (BE) | 1998-01-21 | — | — | EP | disclosed |
| WO-1996031486-A1 | 1,3-DIHYDRO-1-(PHENYLALKENYL)-2H-IMIDAZOL-2-ONE DERIVATIVES HAVING PDE IV AND CYTOKINE INHIBITING ACTIVITY | JANSSEN PHARMACEUTICA N.V. (BE) | 1996-10-10 | — | — | WO | disclosed |
| WO-1996031487-A1 | 1,3-DIHYDRO-2H-IMIDAZOL-2-ONE DERIVATIVES HAVING PDE IV AND CYTOKININ INHIBITING ACTIVITY | JANSSEN PHARMACEUTICA N.V. (BE) | 1996-10-10 | — | — | WO | disclosed |
| WO-1996031485-A1 | 1,3-DIHYDRO-1-(PHENYLALKYL)-2H-IMIDAZOL-2-ONE DERIVATIVES HAVING PDEIV AND CYTOKINE ACTIVITY | JANSSEN PHARMACEUTICA N.V. (BE) | 1996-10-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020068830-A1 | 1,3-DIHYDRO-1-(PHENYLALKYL)-2H-IMIDAZOL-2-ONE DERIVATIVES | HRH2, CBR1, HRH1 | ALDH1A1 351/4885POLB 1677/4885CYP2C19 383/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.